Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Scott D SolomonBrian L ClaggettZi Michael MiaoRafael DiazG Michael FelkerJohn J V McMurrayMarco MetraRamón CorbalánGerasimos S FilippatosAssen R GoudevViatcheslav MareevPranas SerpytisThomas SuterMehmet Birhan YilmazFaiez ZannadStuart KupferStephen B HeitnerFady I MalikJohn R TeerlinkPublished in: European heart journal (2022)
Patients in AFF at baseline were less likely to benefit from omecamtiv mecarbil than patients without AFF, although the attenuation of the treatment effect was disproportionally concentrated in patients with AFF who were also receiving digoxin.Clinical Trial Registration: NCT02929329.
Keyphrases
- heart failure
- end stage renal disease
- clinical trial
- atrial fibrillation
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- phase ii
- left ventricular
- open label
- phase iii
- combination therapy
- acute heart failure
- left atrial
- left atrial appendage